Impact Factor 4.019

The world's most-cited Microbiology journal

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2018.02738

Proteasomal Degradation Machinery: Favourite target of HIV-1 proteins

 Akhil C. Banerjea1*, SnehLata Gupta1 and Ritu Mishra1
  • 1National Institute of Immunology (NII), India

Proteasomal degradation pathways play a central role in regulating a variety of cellular functions of proteins by controlling not only their turnover but also physiological behaviour of the cell. This makes it an attractive target for the pathogens especially viruses which rely on the host cellular machinery for their propagation and pathogenesis. Viruses have evolutionarily developed various strategies to manipulate the host proteasomal machinery thereby creating cellular environment favourable for their own survival and replication. Human Immunodeficiency Virus – 1 (HIV-1) is one of the most dreadful viruses which has rapidly spread throughout the world and caused high mortality due to its high evolution rate. Here, we review the various mechanisms adopted by HIV-1 to exploit the cellular proteasomal machinery in order to escape the host restriction factors and components of host immune system in order to support its own multiplication and establish a successful infection.

Keywords: Proteasome, Proteasome 20S, Ubiquitination, Deubiquitinase (DUB), HIV-1, Tat, NQO1 = quinone oxidoreductase 1

Received: 16 Sep 2018; Accepted: 26 Oct 2018.

Edited by:

Akihide Ryo, Yokohama City University, Japan

Reviewed by:

Yoshinao Kubo, Nagasaki University, Japan
Keisuke Shindo, Kyoto University, Japan  

Copyright: © 2018 Banerjea, Gupta and Mishra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Akhil C. Banerjea, National Institute of Immunology (NII), New Delhi, India,